title: Development of immunotoxins for potential clinical use in Hodgkin's disease.
abstract: During the last decade, immunotoxins (ITs) consisting of a cell-binding moiety and a potent toxin were developed as a new class of biological anti-tumor agents. Hodgkin's disease has shown to be one of the best targets for immunotoxins, as lymphocyte activation markers such as CD25 and CD30 are expressed on Hodgkin and Reed-Sternberg (H-RS)-cells in large numbers. Several immunotoxins against these antigens, which are expressed physiologically only on a small subset of activated hematopoietic cells have demonstrated potent anti-tumor effects both, in vitro and in animal models. Here we summarize the experimental and recent clinical data of using ITs in Hodgkin's disease.
authors.affiliation: Klinik I für Innere Medizin, Universität zu Köln, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Barth
authors.forename: R
authors.initials: R
authors.lastname: Schnell
authors.forename: V
authors.initials: V
authors.lastname: Diehl
authors.forename: A
authors.initials: A
authors.lastname: Engert
mesh_terms: D002986:Clinical Trials as Topic; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use*
chemical_list: D000922:Immunotoxins